Targeting the Urotensin II/UT G Protein-Coupled Receptor to Counteract Angiogenesis and Mesenchymal Hypoxia/Necrosis in Glioblastoma.
UT receptor
angiogenesis
biased ligand
glioblastoma
necrosis
urotensin II
Journal
Frontiers in cell and developmental biology
ISSN: 2296-634X
Titre abrégé: Front Cell Dev Biol
Pays: Switzerland
ID NLM: 101630250
Informations de publication
Date de publication:
2021
2021
Historique:
received:
12
01
2021
accepted:
11
03
2021
entrez:
3
5
2021
pubmed:
4
5
2021
medline:
4
5
2021
Statut:
epublish
Résumé
Glioblastomas (GBMs) are the most common primary brain tumors characterized by strong invasiveness and angiogenesis. GBM cells and microenvironment secrete angiogenic factors and also express chemoattractant G protein-coupled receptors (GPCRs) to their advantage. We investigated the role of the vasoactive peptide urotensin II (UII) and its receptor UT on GBM angiogenesis and tested potential ligand/therapeutic options based on this system. On glioma patient samples, the expression of UII and UT increased with the grade with marked expression in the vascular and peri-necrotic mesenchymal hypoxic areas being correlated with vascular density.
Identifiants
pubmed: 33937253
doi: 10.3389/fcell.2021.652544
pmc: PMC8079989
doi:
Types de publication
Journal Article
Langues
eng
Pagination
652544Informations de copyright
Copyright © 2021 Le Joncour, Guichet, Dembélé, Mutel, Campisi, Perzo, Desrues, Modzelewski, Couraud, Honnorat, Ferracci, Marguet, Laquerrière, Vera, Bohn, Langlois, Morin, Gandolfo and Castel.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
PLoS One. 2011;6(8):e23902
pubmed: 21901144
Neuro Oncol. 2014 Dec;16(12):1575-84
pubmed: 25082799
J Cell Biochem. 2011 Jan;112(1):341-53
pubmed: 21080343
J Pharmacol Exp Ther. 2004 Oct;311(1):204-12
pubmed: 15146030
J Clin Oncol. 2011 Jan 10;29(2):142-8
pubmed: 21135282
Br J Cancer. 2001 Nov 2;85(9):1396-9
pubmed: 11720480
Pharmacol Ther. 2015 Aug;152:63-82
pubmed: 25944528
Nature. 1999 Sep 16;401(6750):282-6
pubmed: 10499587
Biochem J. 2010 Apr 28;428(1):113-24
pubmed: 20192922
Brain Tumor Pathol. 2012 Apr;29(2):73-86
pubmed: 22218709
Am J Pathol. 2013 Oct;183(4):1293-1305
pubmed: 23928381
Glia. 2014 Jul;62(7):1015-23
pubmed: 24715652
J Thromb Haemost. 2008 May;6(5):726-36
pubmed: 18284603
J Immunol. 2007 Jul 15;179(2):901-9
pubmed: 17617581
Folia Neuropathol. 2012;50(4):301-21
pubmed: 23319187
J Exp Clin Cancer Res. 2014 Jun 03;33:48
pubmed: 24893613
Neuro Oncol. 2008 Aug;10(4):617-23
pubmed: 18477765
FASEB J. 2005 Nov;19(13):1872-4
pubmed: 16141364
Oncol Lett. 2012 Dec;4(6):1259-1263
pubmed: 23226801
Cancer Cell. 2010 Jan 19;17(1):98-110
pubmed: 20129251
Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15803-8
pubmed: 9861051
Cancer Ther. 2009 Apr 14;7(A):254-267
pubmed: 20651940
Proc Natl Acad Sci U S A. 2011 Mar 1;108(9):3749-54
pubmed: 21321221
Nucl Med Biol. 2015 Dec;42(12):923-30
pubmed: 26410810
Neuroscience. 2014 Oct 10;278:222-36
pubmed: 25158675
J Hypertens. 2008 Jun;26(6):1119-26
pubmed: 18475149
Tumour Biol. 2017 Apr;39(4):1010428317698357
pubmed: 28443460
Acta Neuropathol. 2014 Sep;128(3):347-62
pubmed: 24722970
J Exp Clin Cancer Res. 2012 Oct 29;31:90
pubmed: 23107277
Autophagy. 2016 Dec;12(12):2344-2362
pubmed: 27715446
Oncogene. 2015 Sep 24;34(39):5080-94
pubmed: 25597409
Cancer Cell. 2012 Mar 20;21(3):309-22
pubmed: 22439926
J Cell Sci. 2012 Feb 15;125(Pt 4):956-64
pubmed: 22399808
Nat Rev Cancer. 2008 Aug;8(8):592-603
pubmed: 18650835
Circ Res. 2020 Jul 3;127(2):310-329
pubmed: 32833569
Biochem Biophys Res Commun. 2003 Oct 24;310(3):860-8
pubmed: 14550283
Oncogene. 2014 Jun 19;33(25):3217-24
pubmed: 23851506
J Chromatogr B Analyt Technol Biomed Life Sci. 2003 Mar 25;786(1-2):215-20
pubmed: 12651017
Curr Opin Neurol. 2009 Dec;22(6):657-64
pubmed: 19770658
J Neurosurg. 2018 Oct 1;:1-11
pubmed: 30497195
Eur J Cancer. 2011 Jul;47(11):1727-35
pubmed: 21458987
Front Immunol. 2018 Apr 05;9:527
pubmed: 29675018
Oncotarget. 2016 May 31;7(22):31955-71
pubmed: 27049916
FASEB J. 2014 Dec;28(12):5148-62
pubmed: 25183668
J Nucl Med. 2014 Nov;55(11):1878-84
pubmed: 25278514
Clin Cancer Res. 2018 Jan 15;24(2):256-258
pubmed: 29133572
Oncotarget. 2015 May 20;6(14):12094-109
pubmed: 25940437
Br J Cancer. 2005 Apr 11;92(7):1247-52
pubmed: 15785746
Eur J Cancer. 2006 Apr;42(6):760-7
pubmed: 16510278
Tohoku J Exp Med. 2009 Dec;219(4):283-8
pubmed: 19966526
Cancer Res. 2016 Oct 1;76(19):5671-5682
pubmed: 27530322
Cell. 2013 Oct 10;155(2):462-77
pubmed: 24120142
Eur J Pharmacol. 2004 Sep 13;498(1-3):83-6
pubmed: 15363979
Front Endocrinol (Lausanne). 2017 Apr 25;8:76
pubmed: 28487672
Int J Mol Med. 2006 Dec;18(6):1107-12
pubmed: 17089015
PLoS One. 2012;7(5):e36319
pubmed: 22563490
Oncotarget. 2015 May 20;6(14):11882-93
pubmed: 25957416
Naunyn Schmiedebergs Arch Pharmacol. 2006 Aug;373(5):381-6
pubmed: 16896801
FASEB J. 2009 Oct;23(10):3424-35
pubmed: 19546305
Biomol Ther (Seoul). 2013 Jul 30;21(4):277-83
pubmed: 24244812
Nature. 2008 Oct 23;455(7216):1061-8
pubmed: 18772890
J Endocrinol. 2019 Jan 1;:
pubmed: 30601760
Eur J Clin Invest. 2014;44(3):285-94
pubmed: 24372535
Peptides. 2009 Jun;30(6):1124-9
pubmed: 19463745
Neuro Oncol. 2009 Dec;11(6):861-70
pubmed: 19401596
Biomed Res Int. 2014;2014:751392
pubmed: 25110692
J Exp Clin Cancer Res. 2019 Feb 18;38(1):87
pubmed: 30777100
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
Biomolecules. 2020 Mar 19;10(3):
pubmed: 32204509
Peptides. 2008 May;29(5):770-7
pubmed: 17900760
J Neurochem. 2006 Oct;99(2):582-95
pubmed: 16942596
Cancer Res. 2017 May 1;77(9):2266-2278
pubmed: 28235764
Arterioscler Thromb Vasc Biol. 2005 Mar;25(3):519-25
pubmed: 15618545
Neurobiol Dis. 2016 Jan;85:227-233
pubmed: 26094595
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
Fluids Barriers CNS. 2013 Mar 26;10(1):16
pubmed: 23531482
Lancet Neurol. 2008 Dec;7(12):1152-60
pubmed: 19007739